Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer

NCT07732413 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Progressive Pediatric Brain Cancer

Interventions

DRUG: NLG802 (indoximod Prodrug)
DRUG: Temozolomide

Sponsor

Lumos Pharma